Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte‐related genes in the mouse brain
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a complex psychiatric illness that manifests as a combination of positive symptoms, negative symptoms, and cognitive deficits. Antipsychotic drugs, such as haloperidol, attenuate dopamine receptor signaling in neurons and constitute the frontline treatment for the positive symptoms of schizophrenia. However, haloperidol treatment has also been reported to exacerbate preexisting negative symptoms/cognitive deficits and the severity of these deficits has been correlated with white matter pathology in schizophrenia. Indeed, several studies implicate oligodendrocyte function in the pathophysiology of schizophrenia, but it is unknown whether these effects are related to drug treatment. It is well established that haloperidol alters gene expression in neurons. However, its effect on oligodendrocytes is unknown. In this study, we investigate the effects of chronic haloperidol treatment on the expression of eight genes known to play critical roles in myelin/oligodendrocyte function. We treated male mice with haloperidol (2 mg/kg/day) for 30 days and measured gene expression changes by using in situ hybridization analysis and quantitative densitometry. Haloperidol caused a decrease in the expression of these genes in several white matter regions of the mouse CNS. In contrast, clozapine (10 mg/kg/day) had no effect on the expression of a subset of these genes. This has important implications for both disease pathology and the consideration of treatment options for patients. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036 · cited 1×
“However, the expression levels of these genes do not appear to correlate well with myelin integrity, insofar as null mutants of these genes exhibit few or no overt myelin defects (Delarasse et al., 2003; Lappe-Siefke et al., 2003).”
BackgroundSeeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 2×
“The typical antipsychotics, including haloperidol, chlorpromazine, and fluphenazine, are primarily dopamine D2 receptor antagonists (Seeman and Lee, 1975; Creese et al., 1976), whereas the \atypical" antipsychotics, such as clozapine, risperidone, quetiapine, and olanzapine, are antagonists at…”
BackgroundWhite Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Mechanisms of axon ensheathment and myelin growth
Sherman, D. L., & Brophy, P. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1743 · Cited by 668
Sanfilipo, M., Lafargue, T., Rusinek, H., Arena, L., Loneragan, C., Lautin, A., Feiner, D., Rotrosen, J., & Wolkin, A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.471 · Cited by 281
Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation
Bartzokis, G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00364-0 · Cited by 179
Cited by
Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia
Takahashi, N., Sakurai, T., Davis, K. L., & Buxbaum, J. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.004 · Cited by 337
Lobo, M. K., Zaman, S., Damez-Werno, D. M., Koo, J. W., Bagot, R. C., DiNieri, J. A., Nugent, A., Finkel, E., Chaudhury, D., Chandra, R., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1875-13.2013 · Cited by 245
“0 (Narayan et al., 2007), or regular drinking water, pH 6.”
BackgroundMethodInfluentialXiao, L., Xu, H., Zhang, Y., Wei, Z., He, J., Jiang, W., Li, X., Dyck, L. E., Devon, R. M., Deng, Y., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002064 · Cited by 191
Chew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154
Sphingolipids in Psychiatric Disorders and Pain Syndromes
Mühle, C., Reichel, M., Gulbins, E., & Kornhuber, J. (2013) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-7091-1511-4_22 · Cited by 58
Metadata
- Authors
- Narayan, S., Kass, K. E., & Thomas, E. A.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2006-12-18
- Volume
- 85
- Issue
- 4
- Pages
- 757-765
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2009279159
- Cited by
- 56
- References
- 8
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte‐related genes in the mouse brain. https://app.cochat.ai/papers/10.1002/jnr.21161
- The paper
- Narayan, S., Kass, K. E., & Thomas, E. A. (2007). Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte‐related genes in the mouse brain. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.21161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.